Evaluation of Health-Related Quality of Life in Lithuanian Brain Tumor Patients Using the EORTC Brain Cancer Module

Adomas Bunevičius1, Šarūnas Tamašauskas1, Arimantas Tamašauskas1, 3, Vytenis Deltuva1, 3
1Department of Neurosurgery, Medical Academy, Lithuanian University of Health Sciences, 2Behavioral Medicine Institute, Medical Academy, Lithuanian University of Health Sciences, 3Neuroscience Institute, Medical Academy, Lithuanian University of Health Sciences, Lithuania

Key Words: brain tumor; health-related quality of life; validity; reliability.

Summary. Background and Objective. Health-related quality of life (HRQoL) is considered an important outcome measure in neuro-oncology. The aim of this study was to evaluate the psychometric properties of the brain cancer-specific Quality of Life Questionnaire (QLQ-BN20) of the European Organization for Research and Treatment of Cancer (EORTC) in Lithuanian brain tumor patients.

Material and Methods. One hundred consecutive patients (71% of women; mean age, 58±14 years) admitted for elective brain tumor surgery were evaluated for HRQoL using the QLQ-BN20, QLQ-C30 (a core EORTC questionnaire for cancer patients), and SF-36 scale; for motor dysfunction (clinical examination); for cognitive dysfunction (Mini-Mental State Examination); and for disability (Barthel Index).

Results. The QLQ-BN20 subscales had an adequate internal consistency (Cronbach α, 0.75–0.90). Motor dysfunction on neurological examination was associated with greater motor dysfunction on the QLQ-BN20; greater disability, with greater future uncertainty, motor dysfunction, communication deficits, headaches, seizures, drowsiness, itchy skin, weakness of legs, and poor bladder control on the QLQ-BN20; and cognitive dysfunction, with greater future uncertainty, visual deficits, motor dysfunction, communication deficits, headaches, drowsiness, and weakness of legs symptoms on the QLQ-BN20, suggesting an adequate clinical validity of the QLQ-BN20. A score for motor dysfunction on the QLQ-BN20 correlated with a score for motor dysfunction on the QLQ-C30 and SF-36 scales; a score for headache on the QLQ-BN20, with a score for pain on the QLQ-C30 and SF-36 scales; and a score for drowsiness symptoms on the QLQ-BN20, with a score for fatigue on the QLQ-C30.

Conclusions. The Lithuanian version of the EORTC-QLQ-BN20 scale has acceptable psychometric properties and can be reliably used for the assessment of HRQoL in brain tumor patients.

Introduction

Brain tumors are a rare disease with an incidence rate of 18 per 100,000 person-years for primary brain tumors and with an estimated overall prevalence rate reaching 222 per 100,000 persons (1). The prognosis of brain tumor is often devastating with an estimated 5-year survival rate reaching approximately 20% for all ages and all tumor types (2–4). In addition, brain tumor patients are subjected to a severe neurological impairment and the increased risk for mental distress and psychiatric comorbidities that can consequentially contribute to deteriorated quality of life (5–8).

Traditional outcome measures in clinical trials evaluating the efficacy of brain tumor treatment include overall survival and progression-free survival among others. However, these classic endpoint measures do not provide with information regarding the burden that brain tumors impose on patients’ functional status and health-related quality of life (HRQoL). Patient-centered outcomes are particularly important in patients with incurable diseases, such as certain brain tumors (7). Hence, the routine assessment of HRQoL is becoming increasingly important as a secondary outcome measure in neuro-oncology (9, 10).

The brain cancer-specific Quality of Life Questionnaire (QLQ-BN20) of the European Organization for Research and Treatment of Cancer (EORTC) (11) was specifically designed for the assessment of HRQoL in brain tumor patients and remains the most widely used HRQoL measure in brain tumor patients (7). A recent study in 17 Eastern and Western European countries reported the adequate psychometric properties of the QLQ-BN20 scale, suggesting that this instrument can be reliably applied for the evaluation of HRQoL in international clinical trials (12). However, to the best of our knowledge, the psychometric properties of the Lithuanian version of the QLQ-BN20 remain to be assessed.
The evaluation of the Lithuanian version of the QLQ-BN20 instrument would provide with more evidence regarding the cross-cultural validity of the QLQ-BN20 instrument and would enable participation in international clinical trails when the QLQ-BN20 is used as a secondary endpoint measure.

Hence, in the current study, the validity and reliability of the QLQ-BN20 in Lithuanian brain tumor patients were evaluated.

**Material and Methods**

**Patients.** In a period from May 2010 until December 2010, consecutive patients admitted for elective brain tumor surgery at the Clinic of Neurosurgery, Hospital of Lithuanian University of Health Sciences, Kaunas, Lithuania, were invited to participate in this cross-sectional study. Patients were not included in the study if they were younger than 18 years, did not speak Lithuanian fluently, or were unable to comprehend study assignments. A total of 126 patients were invited to participate in the study. However, 24 patients (19%) refused to participate in the study, and 2 patients (2%) did not complete all the study assignments and were excluded from further analyses. Hence, our final study sample consisted of 100 patients (71% of women; mean age, 58±14 years). There were no differences in sociodemographic and clinical characteristics between patients who did not agree to participate in the study and those who were studied (all P>0.05).

The study and its consent procedures were approved by the Ethics Committee for Biomedical Research at the Lithuanian University of Health Sciences, Kaunas, Lithuania. Written informed consent was obtained from each study patient.

**Study Design.** The patients were approached within 3 days of admission to the inpatient unit. During the same visit, the patients were assessed for the following: 1) HRQoL using the QLQ-BN20 (11, 12), the QLQ-C30 (version 3.0) (13), and the 36-Item Short Form Medical Outcome Questionnaire (SF-36) (14); 2) symptoms of depression and anxiety using the Hospital Anxiety and Depression scale (HADS) (15); 3) disability using the Barthel Index (BI) (16); and 4) cognitive functions using the Mini-Mental State Examination (MMSE) (17). Medical records were reviewed for the presence of motor dysfunction on neurological examination and for the brain tumor pathology reports. The Lithuanian version of the QLQ-C30 was obtained from the EORTC, and the Lithuanian translation of the QLQ-BN20 was performed according to the EORTC standards.

**Questionnaires.** The QLQ-C30 was established for the evaluation of functional status and symptoms in different populations of cancer patients and is a core EORTC questionnaire (13). The QLQ-C30 contains 30 items that comprise 9 multi-item and 6 single-item scales designed to assess for global health status (2 items); functional status (5 items); role functioning (2 items); emotional functioning (4 items); cognitive functioning (2 items); social functioning (2 items); fatigue (3 items); nausea and vomiting (2 items); pain (2 items); dyspnea (1 item); insomnia (1 item); appetite loss (1 item); constipation (1 item); diarrhea (1 item); and financial difficulties (1 item). Items and scale scores are linearly transformed to a 0–100 scale with higher scores indicating better HRQoL on global health status and functional status scales, and worse HRQoL on symptom scales.

The QLQ-BN20 was specifically designed as the QLQ-C30 supplement for the evaluation of HRQoL in brain tumor patients (11). The QLQ-BN20 is a 20-item self-rating instrument that aggregates into 4 multi-item scales of future uncertainty (4 items), visual disorder (3 items), motor dysfunction (3 items), communication deficits (3 items); and 7 single-item scales of headaches, seizures, drowsiness, itchy skin, hair loss, weakness of legs, and bladder control. All scale scores and items are linearly transformed to a 0–100 scale with higher scores indicating more severe symptoms. The 11-scale structure of the QLQ-BN20 was previously confirmed using the multitrait scaling analysis in large samples of brain tumor patients (11, 12).

The MMSE, BI, and the motor deficits on neurological examination were chosen as anchors against which the known-group validity of the QLQ-BN20 and QLQ-C30 was tested. The MMSE (17) is widely used in clinical practice for the assessment of cognitive functions (18) with total scores ranging between 0 and 30. Greater scores indicate better cognitive function. In the current study, good cognitive function was considered as an MMSE score of >24, and poor cognitive function was considered as an MMSE score of <24.

The BI (16) is routinely used in clinical practice for the assessment of disability in neurologic patients (19). The BI contains 10 items that evaluate daily functions of dressing, bathing, feeding, grooming, transfers from bed to chair and back, bladder and bowel control, toilet use, mobility, and climbing stairs. Each item is scored as 0, 5, 10, or 15, depending on the person’s ability to perform the activity. The global BI score ranges from 0 to 100 points with higher scores indicating lesser disability. In the current study, patients were dichotomized according to the median BI scores in our cohort as optimal functional status (BI score, 100) and suboptimal functional status (BI score, <100).

Finally, the SF-36 (14) and the HADS (15) were chosen for the assessment of construct validity of the QLQ-BN20. The SF-36 is a multi-item self-rating
The HADS (15) is a 14-item, self-rating scale designed for the assessment of depressive (HADS-D) and anxiety (HADS-A) symptoms in somatic patients and is well-validated in Lithuanian inpatients and outpatient somatic patients (22–24). Possible scores on both subscales range from 0 to 21 with higher scores indicating more severe respective symptoms.

Statistical Analysis. First, the internal consistency of the QLQ-BN20 and QLQ-C30 multi-item subscales using the Cronbach’s coefficient α was evaluated. Next, by using the independent-sample t test, we assessed the clinical validity of the QLQ-BN20 by evaluating the ability of the questionnaire to distinguish between known subgroups of patients with respect to motor dysfunction on neurological examination, disability, and cognitive functions. We hypothesized the following: 1) patients with motor dysfunction when compared with patients without motor dysfunction would have a greater symptom severity on the QLQ-BN20 scales of motor dysfunction and weakness of legs; 2) patients with suboptimal functional status (BI score of <100) when compared with patients with optimal functional status (BI score of 100) would have greater future uncertainty and physically oriented symptoms on the QLQ-BN20 scales; and 3) patients with poor cognitive functions (MMSE score of ≤24) when compared with patients with good cognitive functions (MMSE score of >24) would have greater communication deficits and drowsiness as well as more symptoms related to increased intracranial pressure, such as headaches and visual deficit, on the QLQ-BN20. Finally, the construct validity of the QLQ-BN20 was evaluated by calculating Spearman correlation coefficients (rho) of QLQ-BN20 scores with QLQ-C30 scores, SF-36 scores, and HADS scores. We expected stronger correlations (Spearman rho of >0.4) between the scores of subscales with a significant conceptual overlap (i.e., motor dysfunction with physical functioning and headache with bodily pain) and much weaker correlations between the scores with a lower conceptual overlap.

Data were analyzed using the PASW for Windows (IBM Corporation, Chicago, Illinois). Data were expressed as mean (standard deviation) and as median and interquartile range (IQR) for quantitative variables and as a number (percentage) for qualitative variables. A two-tailed P value of <0.05 was considered significant.

Table 1. Demographic and Clinical Characteristics of Study Patients (n=100)

<table>
<thead>
<tr>
<th>Demographic Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD), median (IQR)</td>
<td>58 (14), 59 (21)</td>
</tr>
<tr>
<td>Gender, n (%)</td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>29 (29)</td>
</tr>
<tr>
<td>Women</td>
<td>71 (71)</td>
</tr>
<tr>
<td>Clinical characteristic</td>
<td></td>
</tr>
<tr>
<td>Tumor type, n (%)</td>
<td></td>
</tr>
<tr>
<td>Meningioma</td>
<td>46 (46)</td>
</tr>
<tr>
<td>High-grade glioma</td>
<td>19 (19)</td>
</tr>
<tr>
<td>Low-grade glioma</td>
<td>2 (2)</td>
</tr>
<tr>
<td>Pituitary tumor</td>
<td>16 (16)</td>
</tr>
<tr>
<td>Acoustic neuroma</td>
<td>7 (7)</td>
</tr>
<tr>
<td>Other</td>
<td>10 (10)</td>
</tr>
<tr>
<td>Motor dysfunction, n (%)</td>
<td>18 (18)</td>
</tr>
<tr>
<td>Barthel index</td>
<td></td>
</tr>
<tr>
<td>Score, mean (SD), median (IQR)</td>
<td>97.3 (7.0), 100 (0)</td>
</tr>
<tr>
<td>Score &lt;100, n (%)</td>
<td>25 (25)</td>
</tr>
<tr>
<td>Mini-Mental State Examination</td>
<td></td>
</tr>
<tr>
<td>Score, mean (SD), median (IQR)</td>
<td>26.4 (4.4), 28 (4)</td>
</tr>
<tr>
<td>Score &lt;24, n (%)</td>
<td>21 (21)</td>
</tr>
</tbody>
</table>

IQR, interquartile range.
Validation of the EORTC Scale

Table 2. Descriptive Statistics and Internal Consistency of the EORTC QLQ-BN20 and QLQ-C30 Subscales

<table>
<thead>
<tr>
<th>QLQ-BN20 scales/ single items*</th>
<th>Number of Items</th>
<th>Mean (SD)</th>
<th>Median (IQR)</th>
<th>Cronbach α</th>
</tr>
</thead>
<tbody>
<tr>
<td>Future uncertainty</td>
<td>4</td>
<td>22.8 (22.5)</td>
<td>17 (40)</td>
<td>0.75</td>
</tr>
<tr>
<td>Visual disorder</td>
<td>3</td>
<td>16.0 (24.3)</td>
<td>0 (33)</td>
<td>0.76</td>
</tr>
<tr>
<td>Motor dysfunction</td>
<td>3</td>
<td>20.4 (27.0)</td>
<td>11 (33)</td>
<td>0.77</td>
</tr>
<tr>
<td>Communication deficit</td>
<td>3</td>
<td>15.3 (26.7)</td>
<td>100 (33)</td>
<td>0.90</td>
</tr>
<tr>
<td>Headaches</td>
<td>1</td>
<td>38.3 (38.9)</td>
<td>33 (67)</td>
<td></td>
</tr>
<tr>
<td>Seizures</td>
<td>1</td>
<td>12.7 (25.9)</td>
<td>0 (0)</td>
<td></td>
</tr>
<tr>
<td>Drowsiness</td>
<td>1</td>
<td>23.3 (31.2)</td>
<td>0 (33)</td>
<td></td>
</tr>
<tr>
<td>Hair loss</td>
<td>1</td>
<td>16.3 (31.6)</td>
<td>0 (33)</td>
<td></td>
</tr>
<tr>
<td>Itchy skin</td>
<td>1</td>
<td>8.7 (22.0)</td>
<td>0 (0)</td>
<td></td>
</tr>
<tr>
<td>Weakness of legs</td>
<td>1</td>
<td>18.0 (28.2)</td>
<td>0 (33)</td>
<td></td>
</tr>
<tr>
<td>Bladder control</td>
<td>1</td>
<td>5.7 (17.1)</td>
<td>0 (0)</td>
<td></td>
</tr>
</tbody>
</table>

| QLQ-C30 scales/single items    | 2              | 56.3 (24.1) | 58 (33)      | 0.92       |

| Functional scales†             |                |            |              |            |
| Physical functioning           | 5              | 76.7 (25.0) | 80 (40)      | 0.81       |
| Role functioning               | 2              | 76.7 (25.0) | 80 (40)      | 0.96       |
| Emotional functioning          | 4              | 70.8 (26.4) | 75 (42)      | 0.90       |
| Cognitive functioning          | 2              | 74.8 (28.4) | 83 (33)      | 0.64       |
| Social functioning             | 2              | 78.3 (27.8) | 92 (33)      | 0.73       |

| Symptoms scales/items*         |                |            |              |            |
| Fatigue                        | 3              | 32.9 (30.0) | 22 (44)      | 0.89       |
| Nausea and vomiting            | 2              | 7.8 (18.9)  | 0 (0)        | 0.77       |
| Pain                           | 2              | 29.3 (32.4) | 17 (50)      | 0.80       |
| Dyspnea                        | 1              | 9.0 (22.1)  | 0 (0)        |            |
| Insomnia                       | 1              | 44.0 (40.4) | 33 (92)      |            |
| Appetite loss                  | 1              | 16.3 (28.6) | 0 (33)       |            |
| Constipation                   | 1              | 16.0 (27.4) | 0 (33)       |            |
| Diarrhea                       | 1              | 5.7 (17.8)  | 0 (0)        |            |
| Financial difficulties         | 1              | 22.7 (31.7) | 0 (33)       |            |

IQR, interquartile range.
*Higher scores indicate a higher level of symptoms. †Higher scores indicate better quality of life and better functioning.

Table 3. Clinical Validity of the EORTC-QLQ-BN20 Scale

<table>
<thead>
<tr>
<th>Item</th>
<th>Motor Dysfunction</th>
<th>Barthel Index</th>
<th>MMSE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Yes</td>
<td>No</td>
<td>P</td>
</tr>
<tr>
<td>Future uncertainty</td>
<td>23.1 (23.3)</td>
<td>22.7 (22.5)</td>
<td>0.94</td>
</tr>
<tr>
<td>Visual disorder</td>
<td>11.7 (20.3)</td>
<td>16.9 (25.1)</td>
<td>0.41</td>
</tr>
<tr>
<td>Motor dysfunction</td>
<td>44.4 (34.5)</td>
<td>15.1 (22.0)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Communication deficit</td>
<td>14.2 (26.4)</td>
<td>15.6 (26.9)</td>
<td>0.84</td>
</tr>
<tr>
<td>Headaches</td>
<td>40.7 (38.9)</td>
<td>37.8 (39.1)</td>
<td>0.77</td>
</tr>
<tr>
<td>Seizures</td>
<td>11.1 (22.9)</td>
<td>13.0 (26.6)</td>
<td>0.78</td>
</tr>
<tr>
<td>Drowsiness</td>
<td>25.9 (31.4)</td>
<td>22.8 (31.4)</td>
<td>0.70</td>
</tr>
<tr>
<td>Hair loss</td>
<td>20.4 (34.6)</td>
<td>15.4 (31.1)</td>
<td>0.55</td>
</tr>
<tr>
<td>Itchy skin</td>
<td>9.3 (25.1)</td>
<td>8.5 (21.5)</td>
<td>0.90</td>
</tr>
<tr>
<td>Weakness of legs</td>
<td>31.5 (33.3)</td>
<td>15.0 (26.3)</td>
<td>0.06</td>
</tr>
<tr>
<td>Bladder control</td>
<td>1.9 (7.9)</td>
<td>6.5 (18.5)</td>
<td>0.10</td>
</tr>
</tbody>
</table>

MMSE, Mini-Mental State Examination. Bold indicates significant differences.

compared with the patients with a BI scores of ≥100 reported significantly greater future uncertainty, motor dysfunction, communication deficits, headaches, seizures, drowsiness, itchy skin, weakness of legs, and poor bladder control on the QLQ-BN20. A score of <24 on the MMSE was associated with greater future uncertainty, visual deficits, motor dysfunction, communication deficits, headaches, drowsiness, and weakness of legs on the QLQ-BN20 scale.

**Construct Validity.** A score for future uncertainty on the QLQ-BN20 scale correlated strongly with the scores for physical functioning and role functioning on the QLQ-C30 (rho=–0.63, P<0.001) and with the HADS-A (rho=0.47, P<0.001) and HADS-D (rho=0.53, P<0.001) scores. A score for motor dysfunction on the QLQ-BN20 correlated well with a score for physical functioning on the SF-36 (rho=–0.60, P<0.001) and scores for fatigue (rho=0.59, P<0.001), physical functioning and role functioning (rhos=–0.58, Ps<0.001) on the QLQ-C30. A score for communication deficit on the QLQ-BN20 correlated with the scores for
cognitive functioning (rho=−0.55, P<0.001) and 
global health status (rho=−0.53) on the QLQ-C30; 
a score for headache on the QLQ-BN20, with the 
scores for pain on the QLQ-C30 scale (rho=0.80) 
and bodily pain on the SF-36 (rho=0.74, P<0.001); 
and a score for drowsiness symptoms on the QLQ-
BN20, with the global health status score on the 
QLQ-C30 (rho=−0.52, P<0.001). The scores for 
visual disorder, seizures, hair loss, itchy skin, and 
bladder control on the QLQ-BN20 scale correlated 
weakly with all QLQ-C30 and SF-36 scores (all rho 
coefficients less than 0.4).

**Discussion**

The results of the present study suggest that the 
QLQ-BN20 scale has acceptable psychometric prop-
erties in Lithuanian brain tumor patients; hence, it 
can be reliably applied for the evaluation of HRQoL 
in clinical practice and research studies. In addition, 
our findings provide further evidence regarding an 
adequate transcultural validity of the QLQ-BN20. 
The completion rate of the QLQ-BN20 was 
high, since only 2 patients did not complete the 
questionnaire, suggesting an adequate Lithuanian 
translation of the scale with respect to the ability 
to comprehend the QLQ-BN20 items. The major-
ity of patients rated their HRQoL at the lower 
end of the questionnaires, indicating a relatively 
mild level of symptoms on admission for surgery. 
A trend for lower ratings on the QLQ-BN20 scales 
was previously reported in a large international 
sample of glial brain tumor patients (12). The QLQ-
BN20 symptoms of headache and drowsiness and 
items evaluating future uncertainty as well as the 
QLQ-C30 symptoms of insomnia and fatigue were 
rated highest. These findings are not surprising 
since our sample was mixed with respect to a brain 
tumor type, and the latter symptoms are not brain 
tumor type specific, but rather suggest deterioration 
in general well-being. The QLQ-BN20 symptoms of 
bladder control, itchy skin, and seizures as well 
as the QLQ-C30 symptoms of dyspnea and diarrhea 
received the lowest ratings. Again, these findings 
can be partially explained by a diverse population 
with respect to a diagnosis of brain tumor because 
seizures are more likely to occur in glial brain tumor 
patients, and itchy skin together with diarrhea are 
the expected side effects of radiation therapy and 
chemotherapy, respectively, which are applied only 
to the selective subgroups of brain tumor patients. 

Importantly, we found the acceptable internal 
consistencies of all QLQ-BN20 multi-item scales 
and of all QLQ-C30 multi-item scales with one ex-
ception of the cognitive functioning scale. These 
findings are in line with previous studies and 
confirm the reliability of the proposed factor structure of 
the QLQ-BN20 and QLQ-C30 (11–13, 25). Lower 
than expected internal consistency of the QLQ-C30 
cognitive functioning scale (Cronbach α=0.63) can 
be partially explained by the fact that the 2 items 
of the scale target concentration (“Have you had 
difficulty in concentrating on things, like reading 
a newspaper or watching television?”) and memory 
(“Have you had difficulty remembering things?”), 
which can represent different manifestations of cog-
nitive dysfunction, can be present in the absence of 
cognitive dysfunction and can represent the inter-
mittent side effects of brain tumor treatment (26). 
Thus, we suggest retaining the original structure of 
the QLQ-BN20 and QLQ-C30. 

The known-group validity analyses confirmed an 
adequate clinical validity of the QLQ-BN20 scale. 
In line with our hypotheses, the patients with motor 
dysfunction on neurological examination reported 
the higher levels of motor dysfunction and weakness 
of legs on the QLQ-BN20, suggesting that the QLQ-
BN20 reliably identified patients with impaired mo-
tor functions. As expected, the lower BI scores were 
associated with greater future uncertainty and with a 
greater severity of physically oriented symptoms on 
the QLQ-BN20. Furthermore, patients with lower 
BI scores reported more communication deficits, 
headaches, seizures, and drowsiness, suggesting that 
these symptoms can significantly interfere with the 
activities of daily living of brain tumor patients. In 
addition, poor cognitive function was associated 
with more communication deficits, drowsiness, and 
greater symptoms related to increased intracranial 
pressure. Poor cognitive function was also related 
to more motor dysfunction and more future uncer-
tainty. The latter findings can be explained by the 
fact that cognitive dysfunction usually occurs in the 
advanced stages of the disease when there are ample 
neurological symptoms (26, 27).

The structural validity of the QLQ-BN20 was 
adequate because the QLQ-BN20 scores for motor 
dysfunction, headache, and drowsiness were associ-
ated with the greater levels of respective symp-
toms assessed using the SF-36 and the QLQ-C30. 
In addition, a score for future uncertainty on the 
QLQ-BN20 was associated with decreased physi-
cal and role functioning and with higher levels of 
mental distress, suggesting that physical functioning 
and mental distress are important determinants of 
how patients perceive their future. It was previously 
shown that future uncertainty was associated with 
a decreased survival of brain tumor patients (28). 
Hence, interventions targeting physical functioning 
and mental health might consequentially improve 
the prognosis of brain tumor patients. Moreover, a 
score for communication deficits on the QLQ-BN20 
was associated with poor cognitive functioning. In-
deed, it is well established that the deterioration of 
cognitive functions leads to communication deficits.
(28), and a communication deficit is among clinical diagnostic criteria for dementia (29, 30, 31). A poor correlation of scores for visual disorders, seizures, hair loss, itchy skin, and bladder control on the QLQ-BN20 with the QLQ-C30 and SF-36 scores can be explained by the fact that the abovementioned symptoms are characteristic of neurological disorders or are the common sequelae of brain tumor treatment. The QLQ-C30 and SF-36 scales are generic HRQoL scales designed for use in different patients’ populations and different populations of cancer patients, respectively, and therefore tap the broader domains of HRQoL rather than brain tumor-specific symptoms. Hence, in brain tumor patients, we recommended using the QLQ-BN20 for the assessment of HRQoL instead of generic HRQoL scales.

The major strength of the current study was the use of widely available and well-validated scales (BI, MMSE, and SF–36) against which the construct and clinical validities of the QLQ-BN20 scale were established. Moreover, an official Lithuanian translation of the QLQ-C30 was obtained from the EORTC, and the Lithuanian translation and validation of the QLQ-BN20 were performed under the EORTC guidance. However, a moderate sample size is a major limitation of our study. In addition, the QLQ-BN20 was applied at one time point; therefore, the test–retest reliability of the QLQ-BN20 was not evaluated. In addition, we and others have previously reported that perceived health status, such as HRQoL and psychological distress symptoms, can change in response to brain tumor treatment (7, 11, 14, 32); hence, further studies should explore the feasibility of the QLQ-BN20 in detecting such changes in Lithuanian brain tumor patients.

**Conclusions**

The results of the current study indicate the acceptable psychometric properties of the EORTC QLQ-BN20 HRQoL scale in Lithuanian brain tumor patients. These findings allow a participation in international clinical trials involving brain tumor patients when the QLQ-BN20 is used as an endpoint measure. Our findings also contribute to the growing body of evidence regarding the transcultural validity of the QLQ-BN20 scale.

**Acknowledgments**

This research was partially funded by a grant (MIP-10315) from the Research Council of Lithuania.

We thank Augustinas Tumienės, Deividas Stukas, Kristina Lukšytė, and Rūta Remeikaitė for their help in data collection.

**Statement of Conflicts of Interest**

The authors state no conflict of interest.

**References**


Received 11 June 2012, accepted 28 December 2012